Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NV › Reno › NPI 1326573536
Physician

Medtrans Reno Casal PLLC

Medtrans Reno Casal PLLC was paid $957K by Medicaid between Jul 2019 and Aug 2022, across 35 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 43% of everything it billed.

33Billing provider infoMEDTRANS RENO CASAL PLLC
RENO, NV 89502
33aNPI1326573536assigned 04/25/2017
28Total paid$957K
24GClaims24,929
24DCodes billed35
24AFirst – last monthJul 2019 – Aug 2022
Compared with peers

Next to other Family Medicine Physician providers in Nevada

Rank by total paid#33 of 388
Median peer was paid$27K
This provider vs. median36×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$20K$40K$60K2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20195,321$262K
202013,475$450K
20215,575$225K
2022558$19K
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
99214 Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity 43% 7,711 5,941 $409K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 13% 1,102 715 $123K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 10% 4,274 2,366 $97K
99215 Doctor's office visit, returning patient (complex)Prolong outpt/office vis 8.3% 1,525 973 $79K
99213 Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity 6.0% 1,492 1,225 $57K
Q3014 Telehealth originating site facility fee 5.6% 2,644 2,101 $53K
99204 Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity 5.0% 579 477 $48K
99205 Prolong outpt/office vis 2.0% 358 273 $19K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.8% 709 385 $17K
90833 Psychotherapy, 30 minutes with patient when performed with an E&M service (add-on) 1.5% 399 336 $15K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1.5% 316 179 $15K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 158 145 $4K
23 more codes
99218 <1% 73 $3K
99490 Ccm add 20min <1% 220 $3K
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 149 $2K
99212 Office or other outpatient visit for the evaluation and management of an established patient, straightforward <1% 72 $2K
90674 <1% 194 $2K
36415 Collection of venous blood by venipuncture <1% 870 $2K
90792 Psychiatric diagnostic evaluation with medical services <1% 13 $2K
82075 <1% 644 $1K
80306 <1% 602 $1K
99211 Office or other outpatient visit for the evaluation and management of an established patient, minimal severity <1% 214 $1K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 88 $863.37
99217 <1% 17 $609.18
99407 <1% 82 $85.54
80305 <1% 50 $44.88
81025 <1% 32 $32.40
90686 <1% 105 $30.30
99000 0% 102 $0.00
J2426 Injection, paliperidone palmitate extended release (invega sustenna), 1 mg 0% 18 $0.00
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 0% 42 $0.00
99401 0% 19 $0.00
H0015 Alcohol and/or drug services; intensive outpatient (treatment program that operates at least 3 hours/day and at least 3 days/week and is based on an individualized treatment plan), including assessment, counseling; crisis intervention, and activity therapies or education 0% 18 $0.00
H2011 Crisis intervention service, per 15 minutes 0% 21 $0.00
90756 0% 17 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialBEUOKAGHAEI, ROYA (SUPERVISOR)
Same official

Other billing entities under BEUOKAGHAEI, ROYA

Full network →
ProviderLocationPaid
Well Care Pharmacy I, LLC Series aLas Vegas, NV$5.63M
Medtrans Medical Nevada Casal PLLCLas Vegas, NV$2.14M
Homebase Care Casal PLLCLas Vegas, NV$14K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.